These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 30321129)
41. Analysis of mushroom exposures in Texas requiring hospitalization, 2005-2006. Barbee G; Berry-Cabán C; Barry J; Borys D; Ward J; Salyer S J Med Toxicol; 2009 Jun; 5(2):59-62. PubMed ID: 19415588 [TBL] [Abstract][Full Text] [Related]
42. [Impact of personality disorders in a sample of 212 homeless drug users]. Combaluzier S; Gouvernet B; Bernoussi A Encephale; 2009 Oct; 35(5):448-53. PubMed ID: 19853718 [TBL] [Abstract][Full Text] [Related]
43. Methylphenidate abuse in Texas, 1998-2004. Forrester MB J Toxicol Environ Health A; 2006 Jun; 69(12):1145-53. PubMed ID: 16728377 [TBL] [Abstract][Full Text] [Related]
45. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Lai MW; Klein-Schwartz W; Rodgers GC; Abrams JY; Haber DA; Bronstein AC; Wruk KM Clin Toxicol (Phila); 2006; 44(6-7):803-932. PubMed ID: 17015284 [TBL] [Abstract][Full Text] [Related]
46. The prevalence and characteristics of homelessness in the NSW substance treatment population: implications for practice. Allan J; Kemp M Soc Work Health Care; 2014; 53(2):183-98. PubMed ID: 24483335 [TBL] [Abstract][Full Text] [Related]
50. COVID-19 and contamination: impact on exposures to alcohol-based hand sanitizers reported to Texas Poison Control Centers, 2020. Phillips T; Schulte JM; Smith EA; Roth B; Kleinschmidt KC Clin Toxicol (Phila); 2021 Oct; 59(10):926-931. PubMed ID: 33605823 [TBL] [Abstract][Full Text] [Related]
51. Work-related health emergency cases due to hydrofluoric acid exposures reported to Texas poison centers. Forrester MB Int J Occup Med Environ Health; 2012 Sep; 25(4):456-62. PubMed ID: 23086633 [TBL] [Abstract][Full Text] [Related]
52. Notes from the field: Severe illness associated with synthetic cannabinoid use - Brunswick, Georgia, 2013. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2013 Nov; 62(46):939. PubMed ID: 24257204 [TBL] [Abstract][Full Text] [Related]
53. Use of synthetic cannabinoids in patients with psychotic disorders: case series. Celofiga A; Koprivsek J; Klavz J J Dual Diagn; 2014; 10(3):168-73. PubMed ID: 25392292 [TBL] [Abstract][Full Text] [Related]
54. Association between sociodemographic factors and exposures and utilization of poison centers in Texas, 1998-2002. Forrester MB J Toxicol Environ Health A; 2005 May; 68(10):755-61. PubMed ID: 16020174 [TBL] [Abstract][Full Text] [Related]
55. Synthetic cannabinoid use in New Zealand: a brief evaluation of inquiries to the New Zealand National Poisons Centre. Schep LJ; Slaughter RJ; Temple WA N Z Med J; 2011 Dec; 124(1347):99-101. PubMed ID: 22237580 [No Abstract] [Full Text] [Related]
56. [Synthetic cannabinoids--the new "legal high" drugs]. Berkovitz R; Arieli M; Marom E Harefuah; 2011 Dec; 150(12):884-7, 937. PubMed ID: 22352277 [TBL] [Abstract][Full Text] [Related]
57. The Future of Substance Abuse Now: Relationships among Adolescent Use of Vaping Devices, Marijuana, and Synthetic Cannabinoids. Tai H; Swartz MD; Marsden D; Perry CL Subst Use Misuse; 2021; 56(2):192-204. PubMed ID: 33412950 [No Abstract] [Full Text] [Related]
58. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014. Palamar JJ; Su MK; Hoffman RS Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258 [TBL] [Abstract][Full Text] [Related]